In 1716 individuals-801 human immunodeficiency virus (HIV)-1-seropositive individuals, 217 high-risk HIV-1-seronegative individuals, and 698 general HIV-1-seronegative individuals-from a Seattle cohort and a Multicenter AIDS Cohort Study cohort, the association between HIV-1 susceptibility and repeat-region polymorphisms in the gene for the dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin-related molecule (DC-SIGNR) was investigated; 16 genotypes were found in the DC-SIGNR repeat region. The DC-SIGNR homozygous 7/7 repeat was found to be associated with an increased risk of HIV-1 infection (17.5% in high-risk HIV-1-seronegative individuals vs. 28.5% in HIV-1-seropositive individuals; ), whereas the DC-SIGNR heterozygous 7/5 repeat P p .0015 tended to be correlated with resistance to HIV-1 infection (35.5% in high-risk HIV-1-seronegative individuals vs. 27.6% in HIV-1-seropositive individuals;
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27.6% in HIV-1-seropositive individuals;
). These P p .0291 findings suggest that DC-SIGNR polymorphisms may influence susceptibility to HIV-1.
Polymorphisms in host genes play critical roles in resistance to HIV-1 infection and in the rate of disease progression [1] .
Dendritic cell (DC)-specific intercellular adhesion molecule-3-grabbing nonintegrin (DC-SIGN) is able to bind the HIV-1 gp120 surface protein with high affinity and to enhance transinfection of T cells by HIV-1 [2] . The DC-SIGN-related molecule (DC-SIGNR) shows functions similar to those of DC-SIGN [3] . Some studies have shown that mRNA encoding the DC-SIGNR is present in DCs, although the level of expression of the DC-SIGNR is lower than that of DC-SIGN [3] [4] [5] . One of our previous studies has detected DC-SIGNR mRNA in DCs and found that most DC-SIGNR transcripts at mucosal HIV-1 transmission sites are alternatively spliced isoforms [6] . Because DCs are among the first cells encountered by HIV-1 during sexual transmission, it has been proposed that HIV-1 uses DCs as carriers to gain entry into lymph nodes, with subsequent infection of CD4 + T cells [2] .
Both DC-SIGN and the DC-SIGNR are organized into 3 domains: an N-terminal cytoplasmic region, a neck region containing 7 repeats of the 23-amino-acid sequence, and a Cterminal domain with homology to C-type lectins [4] . One of our recent studies has indicated that polymorphisms in the DC-SIGN repeat region reduce the risk of HIV-1 infection [7] . The DC-SIGNR repeat region is polymorphic [3, 8] . The present study assessed, in both a Seattle cohort and a Multicenter AIDS Cohort Study (MACS) cohort, whether polymorphisms in the DC-SIGNR repeat region could affect HIV-1 susceptibility and subsequent disease progression in (1) multiply exposed HIV-1-seronegative or high-risk HIV-1-seronegative individuals, (2) general HIV-1-seronegative individuals, and (3) HIV-1-positive individuals.
Subjects and methods. Informed consent was obtained from all subjects, and human-experimentation guidelines of the US Department of Health and Human Services and of the authors' institutions were followed during the collection of clinical samples. After 17 individuals (10 from the Seattle cohort and 7 from the MACS cohort) who were homozygous for CCR5-D32 had been excluded, a total of 1716 individuals-1109 from the Seattle cohort and 607 from the MACS cohortwere evaluated.
The Seattle cohort, which was enrolled at the Fred Hutchinson Cancer Research Center Vaccine Trials Unit and the University of Washington Primary HIV Infection Clinic between 1993 and 2004, was evaluated after 10 HIV-1-seronegative individuals (3 of whom were from the multiply exposed group) who were homozygous for CCR5-D32 [7] had been excluded; the remaining 1109 individuals included 94 HIV-1-seronegative individuals who had been multiply exposed to HIV-1 through unprotected sexual activity with partners known to be HIV-1 positive, 698 general HIV-1-seronegative individuals, and 317 HIV-1-seropositive individuals. Of the 317 HIV-1-seropositive individuals, 230 were seroconverters who were estimated to have been infected between their last seronegative HIV-1 test and their first seropositive HIV-1 test. The 94 multiply exposed HIV-1-seronegative individuals were selected because they were healthy HIV-1-seronegative adult volunteers who had engaged in unprotected penile/vaginal or anal sex with a known HIV-1-seropositive individual either (1) more than 5 times during the 6 months prior to entry into the study or (2) more than 2 times per week for a period of 4 months during the 2 years prior to entry into the study. Details of eligibility for entry into the study, as well as additional epidemiologic features of the multiply exposed HIV-1-seronegative individuals, have been provided elsewhere [7, 9] .
The MACS cohort was evaluated after 7 individuals who were homozygous for CCR5-D32 were excluded; the remaining 607 individuals included 123 high-risk HIV-1-seronegative individuals and 484 HIV-1-seropositive individuals. Of the 484 HIV-1-seropositive individuals, 452 were seroconverters who were estimated to have been infected between their last seronegative HIV-1 test and their first seropositive HIV-1 test. The inclusion of the high-risk HIV-1-seronegative individuals and the HIV-1-seropositive individuals was based on criteria described elsewhere [10] [11] [12] [13] .
The DC-SIGNR repeat region was genotyped by use of the following pair of primers: L28 (5 -TGTCCAAGGTCCCCAGC-TCCC-3 ) and L32 (5 -GAACTCACCAAATGCAGTCTTCAA-ATC-3 ) [3] . Polymerase chain reaction (PCR) amplification was performed in a volume of 50 mL containing 0.25 mmol/L of each dNTP, 1.0 mmol/L of each primer, 2.5 mmol/L MgCl 2 , and 1.0 U of Expand High Fidelity PCR System Enzyme in 1ϫ reaction buffer (Boehringer Mannheim). The cycle conditions were as follows: 94ЊC for 5 min, followed by 35 cycles of 94ЊC for 5 s and 70ЊC for 1 min and by 1 cycle of 70ЊC for 10 min.
Alleles were differentiated on the basis of 3%-agarose gel electrophoresis and ethidium-bromide staining.
A x 2 test was used to determine whether the distribution of DC-SIGNR repeat-region genotypes was independent of whether the group studied was high-risk HIV-1 seronegative or HIV-1 seropositive. In the combined Seattle-MACS cohort, there were 5 genotypes-5/5, 6/5, 7/5, 7/6, and 7/7-that were present at frequencies of 15.0%. All of the other, rarer genotypes (i.e., those that were present at frequencies of !5.0%) were considered as a single group. A
contingency table was used to analyze the 3 ϫ 6 association between the genotype and the risk of HIV-1 infection. Because CCR5-D32 homozygosity confers high resistance to HIV-1 infection, the 17 individuals who were homozygous for CCR5-D32 were excluded from these and further analyses.
was considered to be statistically significant.
The correlation between the presence of a particular genotype and the risk of HIV-1 was evaluated by use of a x 2 test; odds ratios (ORs) and 95% confidence intervals (CIs) were calculated. All P values are 2-sided. Because there were 6 genotype comparisons, the significance level, a, was adjusted to 0.0083 (0.05/6). All statistical analyses were performed by use of PRISM (version 4.0) and InStat (version 3.0) (GraphPad Software).
Results. Among the 1716 individuals in the combined Seattle-MACS cohort, there were 16 different genotypes in the DC-SIGNR repeat region (table 1); the allele frequencies in this combined cohort were 0.06% for allele 3, 2.53% for allele 4, 29.36% for allele 5, 15.24% for allele 6, 53.12% for allele 7, 0.15% for allele 8, and 1.54% for allele 9 (table 2), which are comparable to the frequencies that have been reported elsewhere [3] .
Of the 16 genotypes identified, 11 were present at frequencies of !5%, thereby limiting the intergroup comparability of these genotypes; therefore, all of these less frequent genotypes were considered as a group, and a contingency table including 3 ϫ 6 this genotype group and the 5 individual genotypes-5/5, 6/5, 7/5, 7/6, and 7/7-present at frequencies of 15 Distribution of DC-SIGN-related repeat-region genotypes among multiply exposed HIV-1-seronegative/high-risk HIV-1-se (table  1) ; overall, the allele frequencies in this cohort were similar to those in the Seattle cohort (table 2) . Within the MACS cohort, the frequency of the DC-SIGNR heterozygous 7/5 genotype among the high-risk HIV-1-seronegative individuals (34.15%) was not significantly different from that among the HIV-1-seropositive individuals (29.34%) ( ), and this was P p .3544 also true of the distribution of DC-SIGNR genotypes in general ( ), although the frequency of the DC-SIGNR ho-P p .3463 mozygous 7/7 genotype tended to be lower among the highrisk HIV-1-seronegative individuals (21.14%) than among the HIV-1-seropositive individuals (27.48%) ( ). P p .1890 Because genotypes often can vary on the basis of ethnic origin, and because most of the subjects in the present study were white, the aforementioned analyses also were performed on white subjects only. In these additional analyses, both the significance and the trend were similar to those seen in the Seattle cohort and the MACS cohort individually and in the combined Seattle-MACS cohort (data not shown).
Discussion. The results of the present study suggest that ). Individuals with the DC-SIGNR heterozygous 7/5 P p .1890 genotype in the DC-SIGNR repeat region were more frequent in the multiply exposed HIV-1-seronegative or high-risk HIV-1-seronegative group, both in the Seattle cohort ( ) P p .0271 and in the combined Seattle-MACS cohort ( ), al-P p .0291 though, because of the adjustment for multiple comparisons, the difference was not statistically significant. Furthermore, in the MACS cohort, individuals with the 7/5 genotype were not significantly more frequent in the high-risk HIV-1-seronegative group (34.2%) than in the HIV-1-seropositive group (29.3%). In a preliminary study, we had found that DC-SIGNR repeatregion polymorphisms had no effect on HIV-1 disease progression measured in terms of time to development of AIDS, time to AIDS-related death, time to !200 CD4 + cells/mm 3 of blood, and viral load (data not shown).
Because other genetic polymorphisms may also affect the risk of HIV-1 infection and disease progression, we also screened the Seattle cohort for polymorphisms including CCR5-D32, CCR5 promoter polymorphisms, CCR2-64I, SDF1-3 A, RANTES-28G and -403A, the coding sequences of CCR5 and RANTES, and the DC-SIGN repeat region [7] . We found that, except for CCR5-D32 homozygosity and DC-SIGN repeatregion variants, no polymorphisms were associated with resistance to HIV-1 infection in the individuals studied [7] . To avoid the potential influence that CCR5-D32 homozygosity and DC-SIGN repeat-region variants might have on the results for the DC-SIGNR, we performed similar analyses after excluding the individuals who were either homozygous for CCR5-D32 or heterozygous for DC-SIGN repeat-region variants; we found that our results for the DC-SIGNR remained the same. These observations strengthen our findings that the DC-SIGNR homozygous 7/7 genotype is associated with an increased risk of HIV-1 infection, whereas the DC-SIGNR heterozygous 7/5 genotype may be associated with a decreased risk of HIV-1 infection.
In contrast to the results of the present study, Lichterfeld et al., in their comparison of 134 healthy volunteers and 391 HIV-1-seropositive individuals, did not detect any association between DC-SIGNR repeat-region polymorphisms and HIV-1 transmission [14] . We suggest that Lichterfeld et al.'s different results can be explained by their study's different cohort structure. To investigate this possibility, we further analyzed the distribution of DC-SIGNR repeat-region genotypes and alleles-comparing it in all of our HIV-1-seronegative subjects versus our HIV-1-seropositive subjects. No significant differences between these 2 groups were revealed, either in the Seattle cohort or in the combined Seattle-MACS cohort; therefore, the probable explanation for Lichterfeld et al.'s failure to detect any association between DC-SIGNR repeat-region polymorphisms and HIV-1 transmission is that their study did not include highly exposed HIV-1-seronegative individuals. The discrepancy between our results and those reported by Lichterfeld et al. highlights the need for a large collaborative metaanalysis, which also has been proposed elsewhere [15] . Our results, from a comparison, in 2 cohorts, of multiply exposed HIV-1-seronegative individuals versus HIV-1-seropositive individuals, suggest that DC-SIGNR polymorphisms may influence susceptibility to HIV-1 infection. However, this association should be interpreted with caution, because we failed to detect any significant difference, in the distribution of DC-SIGN repeat-region genotypes, between the general HIV-1-seronegative individuals and the HIV-1-seropositive individuals, which suggests that these associations, although statistically significant, may be biologically minor. Nonetheless, the mechanism whereby DC-SIGNR repeat-region polymorphisms affect HIV-1 transmission remains an area for future study and has the potential to affect the prevention of HIV-1 transmission.
